Cargando…

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib

Prognostic classifications for patients treated with sorafenib for hepatocellular carcinoma (HCC) facilitate stratification in trials and inform clinical decision making. Recently, 3 different prognostic models (hepatoma arterial-embolization prognosis [HAP] score, sorafenib advanced HCC prognosis [...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sansone, Vito, Tovoli, Francesco, Casadei-Gardini, Andrea, Di Costanzo, Giovan Giuseppe, Magini, Giulia, Sacco, Rodolfo, Pressiani, Tiziana, Trevisani, Franco, Rimini, Margherita, Tortora, Raffaella, Nardi, Elena, Ielasi, Luca, Piscaglia, Fabio, Granito, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808555/ https://www.ncbi.nlm.nih.gov/pubmed/33443944 http://dx.doi.org/10.14309/ctg.0000000000000286

Ejemplares similares

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders
por: Ielasi, Luca, et al.
Publicado: (2021)

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

Child Pugh and ALBI grade: past, present or future?
por: Rimini, Margherita, et al.
Publicado: (2020)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

Celiac Disease Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis
por: Tovoli, Francesco, et al.
Publicado: (2018)

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis
por: Cortese, Andrea, et al.
Publicado: (2023)

Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
por: Marinelli, Sara, et al.
Publicado: (2013)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
por: Burgio, Valentina, et al.
Publicado: (2021)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

COVID-19: Has the Liver Been Spared?
por: Brandi, Nicolò, et al.
Publicado: (2023)

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment
por: Personeni, Nicola, et al.
Publicado: (2022)

Predictive scores for hepatocellular carcinoma: a race with no winners?
por: Tortora, Raffaella, et al.
Publicado: (2020)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Risk of Drop-Out from Follow-Up Evaluations for Celiac Disease: Is It Similar for All Patients?
por: Tovoli, Francesco, et al.
Publicado: (2022)

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Ferri, Silvia, et al.
Publicado: (2022)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5)
por: Terzi, Eleonora, et al.
Publicado: (2022)

Hot topics in hepatocellular carcinoma
por: Ielasi, Luca, et al.
Publicado: (2019)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for COVID-19 Pandemic
por: Raiteri, Alberto, et al.
Publicado: (2021)

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
por: Tovoli, Francesco, et al.
Publicado: (2018)

Current guidelines for the management of celiac disease: A systematic review with comparative analysis
por: Raiteri, Alberto, et al.
Publicado: (2022)

Autoantibodies to speckled protein family in primary biliary cholangitis
por: Granito, Alessandro, et al.
Publicado: (2021)

Anti-ganglioside antibodies and celiac disease
por: Granito, Alessandro, et al.
Publicado: (2021)

Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia
por: Ielasi, Luca, et al.
Publicado: (2023)

Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib
por: Sapena, Víctor, et al.
Publicado: (2022)

Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery
por: Goio, Elisabetta, et al.
Publicado: (2020)

Hepatic Steatosis in Patients with Celiac Disease: The Role of Packaged Gluten-Free Foods
por: Raiteri, Alberto, et al.
Publicado: (2022)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
por: De Lorenzo, Stefania, et al.
Publicado: (2022)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

The Perceived Ability of Gastroenterologists, Hepatologists and Surgeons Can Bias Medical Decision Making
por: Cucchetti, Alessandro, et al.
Publicado: (2020)

Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case–control study
por: Morisco, Filomena, et al.
Publicado: (2018)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease
por: Tovoli, Francesco, et al.
Publicado: (2017)

Response to: “Comment on Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma”
por: Famularo, Simone, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_94ovjlrv9qeu46hlajh30r21t8